MOTPOLY XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Motpoly Xr, and what generic alternatives are available?
Motpoly Xr is a drug marketed by Aucta and is included in one NDA. There are three patents protecting this drug and two Paragraph IV challenges.
This drug has fifteen patent family members in twelve countries.
The generic ingredient in MOTPOLY XR is lacosamide. There are twenty-two drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Motpoly Xr
A generic version of MOTPOLY XR was approved as lacosamide by ALEMBIC on March 17th, 2022.
Paragraph IV (Patent) Challenges for MOTPOLY XR
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MOTPOLY XR | Extended-release Capsules | lacosamide | 100 mg and 150 mg | 216185 | 1 | 2026-02-10 |
| MOTPOLY XR | Extended-release Capsules | lacosamide | 200 mg | 216185 | 1 | 2025-12-29 |
US Patents and Regulatory Information for MOTPOLY XR
MOTPOLY XR is protected by six US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-001 | May 4, 2023 | RX | Yes | No | 11,337,943 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-002 | May 4, 2023 | RX | Yes | No | 11,337,943 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Aucta | MOTPOLY XR | lacosamide | CAPSULE, EXTENDED RELEASE;ORAL | 216185-001 | May 4, 2023 | RX | Yes | No | 11,883,374 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MOTPOLY XR
See the table below for patents covering MOTPOLY XR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 3148705 | COMPOSITION PHARMACEUTIQUE DE LACOSAMIDE ET SA PREPARATION PHARMACEUTIQUE (LACOSAMIDE PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL PREPARATION THEREOF) | ⤷ Start Trial |
| China | 112043681 | 一种拉考沙胺药物组合物及其药物制剂 (Lacosamide pharmaceutical composition and pharmaceutical preparation thereof) | ⤷ Start Trial |
| China | 114173763 | 一种拉考沙胺药物组合物及其药物制剂 (Lacosaxamide pharmaceutical composition and pharmaceutical preparation thereof) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MOTPOLY XR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0888289 | C300376 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829 |
| 0888289 | 09C0006 | France | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829 |
| 0888289 | SPC/GB09/007 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch